P. C. Boutros

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas

This study investigates the relationship between CDKN2A mRNA expression and clinical outcomes in meningiomas, finding that high expression is associated with poorer progression-free survival and more aggressive tumor characteristics.

The landscape of drug sensitivity and resistance in sarcoma

This study uses patient-derived tumor organoids to identify drug sensitivity and resistance patterns in sarcoma, finding actionable treatment regimens for 59% of tested specimens.

Germline determinants of the prostate tumor genome

The paper identifies germline-determined quantitative trait loci (dQTLs) that influence somatic mutational features in prostate cancer, revealing their impact on tumor epigenome, transcriptome, and proteome.

Drug screening at single-organoid resolution via bioprinting and interferometry

The paper develops a method to screen drugs at single-organoid resolution using bioprinting and interferometry to identify treatment responses in tumor organoids.

Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

This study characterizes intra-tumor heterogeneity across 2,658 human cancer genomes, identifying subclonal mutations and evolutionary patterns across 38 cancer types.

Cis-Regulatory Element Hijacking by Structural Variants Overshadows Higher-Order Topological Changes in Primary Prostate Cancer

The paper shows that structural variants causing cis-regulatory element hijacking have a greater impact on gene expression than changes in three-dimensional chromatin topology in primary prostate cancer.

Quantifying the Influence of Mutation Detection on Tumour Subclonal Reconstruction

This study evaluates subclonal reconstruction pipelines for prostate cancer, showing significant variability and biases in predicting subclonal architecture and mutation timing.

NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4

This study identifies NOX4 as a link between metabolic deregulation and ER-specific redox vulnerability in PDAC, suggesting PRDX4 as a therapeutic target for pancreatic cancer.

Ancestry Influences on the Molecular Presentation of Tumours

This study examines how ancestry affects the mutational landscape of tumors across 12,774 samples, finding ancestry influences mutation counts, timing, and specific mutational signatures.

Age Influences on the Molecular Presentation of Tumours

This study examines how age affects the mutational landscape of tumors across 35 cancer types, revealing age-related differences in mutation numbers, timing, and clinical outcomes.

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

This study uses whole-genome sequencing to identify four distinct genotypes in metastatic castration-resistant prostate cancers, with potential clinical implications for patient stratification.

Divergent mutational processes distinguish hypoxic and normoxic tumours

This study identifies hypoxia-associated mutational processes and genomic features across 1,188 tumours from 27 cancer types, showing hypoxia increases mutational load and influences driver mutations and evolutionary trajectories.

Sex Differences in Oncogenic Mutational Processes

This study analyzes sex differences in whole genome mutational processes across 1,983 tumors from 28 subtypes, revealing sex-biased mutations in coding and non-coding regions and mutational signatures.

The evolutionary history of 2,658 cancers

This study uses whole-genome sequencing of cancer samples to reconstruct the evolutionary history of 39 cancer types, identifying early and late-stage mutational patterns and driver genes.

Modeling the MYC-driven normal-to-tumour switch in breast cancer.

This study creates an in vivo model of MYC-driven breast cancer by combining PIK3CAH1047R mutation with deregulated MYC, showing a normal-to-tumour switch and dependence on MYC for tumor growth.

Candidate cancer driver mutations in super-enhancers and long-range chromatin interaction networks

The paper identifies 41 frequently mutated regulatory elements in cancer genomes, enriched in non-coding mutations and linked to gene expression control through chromatin interactions.